ARCHIVES

Troubles of Two Landmark Cancer Drugs, Celebrex and Iressa, Likely to Shape cancer Prevention, FDA Policy. FDA Mulls Withdrawal of Iressa.

This article is from The Cancer Letter archive.

Vol. 31 No. 01 | January 7, 2005

Download PDF Visit The Full Archive

Related Articles

New NCI Director Proposes $9 Million Community Cancer Centers Program.

September 8, 2006

Turmoil in Texas: SEC Issues Subpoena to AVEO on Tivozanib

July 12, 2013

DRG Regulation Opponents May Have Powerful New Ally

November 25, 1983

Senate Markup Would Give NCI $985 Million, Offers Prospect That Reductions In Grants Will Be Restored

December 10, 1982

NCI Implementing Changes In Organ Site Program, Directing Grant applications To NIH Study Sections

October 15, 1982

GAO Study Finds Lumpectomy Effective As Mastectomy In Trials And In Practice

November 25, 1994